Update on antiphospholipid antibodies: Clinical significance

Angela Tincani, Tamara Ziglioli, Laura Andreoli, Pierluigi Meroni

Research output: Contribution to journalArticlepeer-review


Antiphospholipid antibodies (aPL) are autoantibodies directed to phospholipid-binding proteins and classically related to thrombosis and pregnancy loss in the so-called antiphospholipid syndrome (APS). A wide spectrum of clinical manifestations have been observed in individuals with aPL. These may be asymptomatic, or they may exhibit clinical features suggesting APS, but not fulfilling the International Classification Criteria; typical APS manifestation in the absence of detectable aPL is defined as seronegative APS; microangiopathic APS may involve either one tissue only or may present with widespread thrombosis episodes accompanied by acute multi-organ failure in the catastrophic syndrome. The detection of different aPL profiles seems to increase the diagnostic specificity of the tests. The future research should focus on the development of assays that selectively identify aPL associated with increased risk of thrombosis or pregnancy complications, in order to lead to therapeutic strategies able to prevent unresolved problems associated with aPL.

Original languageEnglish
Pages (from-to)551-560
Number of pages10
JournalInternational Journal of Clinical Rheumatology
Issue number5
Publication statusPublished - 2009


  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Update on antiphospholipid antibodies: Clinical significance'. Together they form a unique fingerprint.

Cite this